Deprescribing in nursing homes: Protocol for nested, randomised controlled hybrid trials of deprescribing interventions.
Deprescriptions
Nursing homes
Patient safety
Pharmaceutical services
Potentially inappropriate medication list
Journal
Research in social & administrative pharmacy : RSAP
ISSN: 1934-8150
Titre abrégé: Res Social Adm Pharm
Pays: United States
ID NLM: 101231974
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
20
05
2020
revised:
25
05
2020
accepted:
25
05
2020
pubmed:
6
7
2020
medline:
3
8
2021
entrez:
6
7
2020
Statut:
ppublish
Résumé
Polypharmacy and the use of potentially inappropriate medication (PIMs) are frequent among nursing home (NH) residents, and are associated with adverse health outcomes like falls, hospitalisation and death. Deprescribing has been proposed as a way to curtail both problems; however, the best way to implement deprescribing and its real impact are still unclear. This article describes nested trials of two consecutive deprescribing interventions, the first at the NH level, and the second at the resident level. The first intervention (QC-DeMo) will be a deprescribing module to be carried out in existing interprofessional quality circles in NHs, with the goal to develop a NH-wide deprescribing consensus. Its effects will be evaluated on the use of PIMs and on patient safety outcomes such as death, hospitalisation and falls. All NHs in the cantons of Vaud and Fribourg with an integrated pharmacy service will be eligible. The second intervention (IDeI), at the resident level, will be a deprescribing-focused medication review, resulting in the implementation of a deprescribing plan. Its effects will be evaluated on the use of PIMs and chronic medications, and on quality of life. This second trial will take place in the NHs allocated to the intervention group of the first trial. All residents of these NHs over 65 years old, living in the NH for at least 4 months, and taking 5 or more medications will be eligible to participate. Both trials will be hybrid effectiveness and implementation trials, aiming to understand the implementation process for the interventions, and to identify barriers and facilitators. Both trials were approved by the relevant ethics committee, registered on ClinicalTrials.gov (QC-DeMo: NCT03688542; IDeI: NCT03655405), and funded by the Swiss National Fund for Scientific Research.
Identifiants
pubmed: 32622774
pii: S1551-7411(20)30609-4
doi: 10.1016/j.sapharm.2020.05.026
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT03688542', 'NCT03655405']
Types de publication
Clinical Trial Protocol
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
786-794Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.